Access to anti-retroviral drugs, male in Eritrea

Eritrea: Access to anti-retroviral drugs, male was 72.0% in 2024. ◆ Volatile

Latest (2024)
72.0%
Change on year
up 1.4%
World rank
65th
of 141 countries
All-time high
72.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Eritrea, 2000–2024

0204060802000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 0 %2005: 3 %2006: 7 %2007: 12 %2008: 17 %2009: 24 %2010: 29 %2011: 34 %2012: 42 %2013: 49 %2014: 56 %2015: 62 %2016: 67 %2017: 62 %2018: 62 %2019: 64 %2020: 70 %2021: 67 %2022: 69 %2023: 71 %2024: 72 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, male in Eritrea stood at 72.0%. That is the highest value across all 25 years on record.

Compared with earlier readings it is up 1.4% on the previous year and up 28.6% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Eritrea peaked at 72.0% in 2024 and was at its lowest, 0.0%, in 2000.

That places Eritrea 65th out of 141 countries with data for 2024, putting it in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Eritrea, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Eritrea, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 0.0%
2005 3.0%
2006 7.0% +133.3%
2007 12.0% +71.4%
2008 17.0% +41.7%
2009 24.0% +41.2%
2010 29.0% +20.8%
2011 34.0% +17.2%
2012 42.0% +23.5%
2013 49.0% +16.7%
2014 56.0% +14.3%
2015 62.0% +10.7%
2016 67.0% +8.1%
2017 62.0% -7.5%
2018 62.0% +0.0%
2019 64.0% +3.2%
2020 70.0% +9.4%
2021 67.0% -4.3%
2022 69.0% +3.0%
2023 71.0% +2.9%
2024 72.0% +1.4%

Averages by decade

DecadeAverage LowestHighest Years
2000s 6.3% 0.0% 24.0% 10
2010s 52.7% 29.0% 67.0% 10
2020s 69.8% 67.0% 72.0% 5

Countries ranked near Eritrea

  1. 62 Chile 73.0% compare
  2. 62 Myanmar 73.0% compare
  3. 62 United Arab Emirates 73.0% compare
  4. 65 Georgia 72.0% compare
  5. 65 Panama 72.0% compare
  6. 65 Tajikistan 72.0% compare

See the full ranking of 160 places →

More gender data for Eritrea

All data for Eritrea →

Frequently asked questions

What is access to anti-retroviral drugs, male in Eritrea?
Access to anti-retroviral drugs, male in Eritrea was 72.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Eritrea?
The highest recorded value was 72.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Eritrea?
The lowest recorded value was 0.0% in 2000.
How does Eritrea rank for access to anti-retroviral drugs, male?
Eritrea ranks 65th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Eritrea?
Over the last ten years it is up 28.6%. The long-run trend across the full record is volatile.
Where does this Eritrea data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Eritrea. Statizoid, drawing on UNAIDS estimates. Retrieved 06 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/eritrea/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/eritrea/">Access to anti-retroviral drugs, male in Eritrea</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.